Post on 20-Jun-2020
Making an Impact – leading d li i iand scaling innovation
D Li MDr Liz Mear, Chair of the National AHSN Network of England Chief Executive, Innovation AgencyLiz.mear@innovationagencynwc.nhs.ukTwitter: @MearLiz 1
AHSNs – improving health& supporting economic growth
English NHS financial context
• The world’s largest public, integrated health serviceservice
• NHS spend £120.15 billion per annum• AHSNs cover all buyers and all providersy p• 209 buyers (clinical commissioning groups)• 258 providers• 7,875 GP practices (with many GPs in each practice)
• 853 for profit and not for profit independent• 853 for‐profit and not‐for‐profit independent sector providers, giving care to NHS patients
• Each AHSN covers a population of between
5
Each AHSN covers a population of between4 and 6 million people
Why AHSNs are uniqueImproving care and enabling Spreading innovation at Improving care and enabling
cash releasing savings - Collaboration with local
transformation & improvement
pace & scale - Support local delivery of FYFV - Support national programmes
e g NIA and Clinical ppartners
- Introducing innovative products/ services to health and care
th
e.g. NIA and Clinical Entrepreneurs
- Improving Patient Safetypathways
Transforming Health,
Generating Efficiencies and
Supporting the NHS to deliver a step change e g
AHSN collaboration Mobilising our shared
ti & t
Efficiencies and Economic Growth
deliver a step change, e.g.- NHS Innovation Accelerator
- Test Beds
expertise & resources to support national spread at
pace & scale (e.g. AF)Brokering with industry and life
6
- Personalised medicine / Genomics Medicine Centres
‐ Brokering with industry and life sciences to play their part in NHS
transformation
Presentation 1
How do we bring the right people together to create a spark – or
fan a flame and break downPresentation 1
fan a flame and break down barriers?
1
8@mearliz
Innovation ScoutsInnovation Scouts
Champions of change, learning from innovation leadersChampions of change, learning from innovation leaders Creating a culture of innovation; part of the AHSN Network for co-creating new technologies and systems
Supporting networks
Presentation 11
10@mearliz
National Innovation
17 8 I i F ll i i h l h
Accelerator17 + 8 Innovation Fellows – innovative health technologies and services into action
Presentation 1
Dr Penny Newman
Francis White spreading the use of Kardia from AliveCor,
Dr Lloyd HumphriesPatient Knows Best
Dr Penny Newman
Dr Matt Jameson Health Unlocked,
the UK’s first mobile heart monitor
Product description: MyCOPDOnline programme for the interactive self‐management of peopleOnline programme for the interactive self management of people with COPD.Problem solved: improving self‐management for patients with severeand very severe COPDLikely demand: 835,000 adults live with COPD in the UK
Evidence base: HealthQuestestimate that the MyCOPD selflive with COPD in the UK,
35%(292,250) who are rated as severe or very severe would be
estimate that the MyCOPD self‐management system can be provided to CCGs for under £20
the target audience for enrolment
per patient. Less than the cost of a one month supply of most COPD inhalers
Fellows represent a range of innovations
Earlier diagnosis Safest, highest quality health care
Brush DJ Non injectable arterialBrush DJAliveCorScarred Liver Project
Non injectable arterial connectorEpiscissors‐60PneuX Prevention System
Supporting people to Digital health
NerveCentre
live healthier lives Digital health
MyCOPDi Thrive
SapientiaJoint Dementia Researchi‐Thrive
SleepioOwiseNeuroResponse
Joint Dementia ResearchHealthUnlockedPatients Know Best
NeuroResponseHealth Coaching
National Innovation
O l
AcceleratorOne example
Presentation 1
Francis White spreading the use of Kardia from AliveCor the UK’s firstKardia from AliveCor, the UK s first mobile heart monitor
Impressive results achieved to date:Impressive results achieved to date:
• 345+ additional NHS providers• 345+ additional NHS providers and commissioners using NIA innovations
• £17m+ raised in funding for life gscience businesses
Clinical EntrepreneursOpportunities for junior doctors to develop their entrepreneurial aspirations during their clinical training period
Launched May 2016 – 100 recruited
8 regional boot camps in coming year8 regional boot camps in coming year including at Alder Hey in November
Alder Hey ‘bat cave’ to be Northern HQ –I ti H b f d d b I ti Presentation 1Innovation Hub, funded by Innovation Agency – ‘living lab’ and VR
Phase 2 Spring 2017 Northern HQ – the Alder Hey ‘bat cave’p g
Recruitment of wider clinical specialties -nurses/pharmacists/allied health professionals
Northern HQ the Alder Hey bat cave
professionals
16@mearliz
Dr Jing Ouyang
Dr Jing Ouyang – Foundation doctor at Aintree has a prototype A h l h i Presentation 1Aergo wheelchair.
Uses airbags to help postural and pressure management. Can be p goperated via a mobile phone.
17@mearliz
Innovation and technology tariff –b ki d b ibreaking down barriers
• Evidence based (with the right clinical specialist ( g padvising on this )
R l t d t th t / t d d NOT d• Related to the outcome/ standard NOT named product
• Where the current reimbursement creates the primary barrier to uptake
• Considered alongside other factors guidance, training etc.
Supporting and developing i l i i i inational initiatives
Support for 5YFV programmes
• Vanguards – 50 new care health and care systemsand care systems
• Healthy New Towns – 76,000 new homes Presentation 1new homes
• Global Digital Exemplar H i l £120 illiHospitals ‐ £120 million
• Test beds – 7 regional sites• 100,000 Genomes project
Test Beds• Frontline health and care workers in seven
areas are pioneering and evaluate the use of novel combinations of interconnected devices such as wearable monitors, data
l i d f ki hi h illanalysis and ways of working which will help patients stay well and monitor their conditions themselves at homePresentation 1conditions themselves at home.
• Successful innovations will then be available for other parts of the country to adopt and adapt to the particular needs of their local populations.
• 10 Dec 2012: Prime Minister announced that Government intended to achieve a paradigm shift in way genomics is used across the NHS–David Cameron committed the UK to sequencing 100,000 wholehuman genomes by the end of 2017
• The 100,000 Genomes Project focused on sequencing the whole genome of patients with rare inherited diseases and certain cancers with Genomics England co‐ordinating
kworkNWCoastGenomicMedicineCentre
100,000 Genome Project ‐ it all started with David Cameronwith David Cameron
• In 2009, David and Samantha's son Ivan Cameron, born (2002) with cerebral palsy and , ( ) p ysevere epilepsy, died in hospital after suffering seizures during the night.
• Though the couple were initially told by doctors• Though the couple were initially told by doctors he was suffering a kidney malfunction, Ivan was eventually diagnosed with Ohtahara syndrome
A l i l di d h i d– A rare neurological disorder characterised by seizures.
'Every child is precious and irreplaceable and the death of a child is an unbearable sorrow that no
parent should ever have to endure.‘David Cameron
The Guardian 25th Feb 2009The Guardian 25 Feb 2009
NWCoastGenomicMedicineCentre
Aim of the ProjectAim of the Project
NWCoastGenomicMedicineCentre
Genomic diagnosis shaping clinical management –neonatal diabetes
• Mutations in >25 different genes cause neonatal diabetes.• New genomic technology has found 5 new genetic subtypes which inform therapy options.
neonatal diabetes
KCNJ11 V59M FOXP3 c 227delTEIF2AK3 p.E371* STAT3 T716MGATA6 c.1448-1455delKCNJ11 p.V59MPermanent diabetes
and developmental delay
Sulphonylurea therapy
FOXP3 c.227delTIPEX
Syndrome
Bone Marrow Transplant
EIF2AK3 p.E371Wolcott Rallison
Syndrome
Liver Transplant
STAT3 p.T716MMulti-organ autoimmune
disease
? STAT3 inhibitor
GATA6 c.1448 1455delSyndromic pancreatic
agenesis
Insulin and exocrine supplements ? STAT3 inhibitor
Five babies; five different treatments
Providing Answers Changing LivesProviding Answers Changing Lives• Jessica, a four year old little
girl• Seizures and epileptic fits since
birth• Anti epileptic drugs were not
controlling her symptomscontrolling her symptoms• Jessica was one of the first
children to be diagnosed through the 100,000 Genomethrough the 100,000 Genome Project
• WGS has shown Jessica has a unique variant causing a di d i l 00disorder seen in only 500 people in the World
• Data sharing globally was vitalThi i t i• This variant was in a gene called SLC2A1
How does this explain Jessica’s ?symptoms?
• The SLC2A1 gene makes a protein thatThe SLC2A1 gene makes a protein that transports a certain type of sugar into the brain.
• Two healthy copies of this gene are needed for this protein to transport enough of this sugar to fuel the brain.
• Mistakes in the SLC2A1 gene can cause ‘Glut1 deficiency syndrome’ – which is Jessica’s diagnosis.
Treatment isn’t Always a Drug• Research shown in
patients who have Glut1 d fi i ddeficiency syndrome, special low‐carbohydrate diet can help reduce seizures
• This ‘ketogenic diet’ provides alternativeprovides alternative energy source to the brain.
• Diet carefully tailored for Jessica
• Jessica’s seizures and fits• Jessica s seizures and fits almost eradicated – 4 wks.
B k f l ti hiBroker of relationships, collaborations and
interoperability
Matching innovations with those h d h h I iwho need them: the Innovation
ExchangegPlatform for:
I ti hi h h d t t d i tInnovations which have demonstrated impact locally and are supported by NHS or social care stakeholders in the North West Coast
Presentation 1
Innovations which have demonstrated impact in other regions and are endorsed by other AHSNs 1Digital innovations which match specific needs to drive improvement in the management of long term conditionsg g
30@mearliz
The Innovation PathwayThe Innovation Pathway
AHSNs help companies & innovators navigate a fragmented landscape
31
C ti t hi ith i d tCreating partnerships with industry
• Working with the LEPs: match funding provided for posts and business support work
• Establishing national forum for AHSNs and Association of British Healthcare Industries (ABHI) and a strong partnership with Association of British g p pPharmaceutical Industries (ABPI)
SBRI Healthcare
• Creating solutions that will improve patient care, improve efficiency for the NHS and enhance economic growth for Befficiency for the NHS and enhance economic growth for Bcompanies.
• NHS England backed programme that provides funding toNHS England backed programme that provides funding to companies to solve healthcare problems.
• 15 Academic Health Science Networks (AHSNs) and NHS Presentation 1England leads to give detailed specifications to industry fo
some of our most pressing health needs.15/16 d d t t ith t t l l f £17 5 t 4• 15/16 awarded contracts with a total value of £17.5m to 4
• companies.
34@mearliz
Thank youAHSN Network activityliz.mear@innovationagencynwc.nhs.ukNorth East & North Cumbria
Health Innovation Networktara.donnelly4@nhs.netWessexNorth East & North Cumbria
Seamus.ONeill@ahsn-nenc.org.ukEast Midlandsmike.hannay@nottingham.ac.uk
bill.gillespie@wessexahsn.netImperial College Health Partnersaxel.heitmueller@imperialcollegehealthpartners comOxford
gary.ford@ouh.nhs.ukEasternsteve feast@eahsn org
althpartners.comWest Midlandschristopher.parker@wmahsn.orgInnovation Agencysteve.feast@eahsn.org
South Westrosie.benneyworth@swahsn.comGreater Manchester
@
liz.mear@innovationagencynwc.nhs.ukWest of Englanddeborah evans@weahsn netmike.burrows@gmahsn.org
UCLPartnersc.davie@ucl.ac.uk
deborah.evans@weahsn.netKent Surrey Sussexguy.boersma@nhs.netYorkshire & Humberrichard.stubbs@yhahsn.com